SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more
SCI Pharmtech Inc (4119) - Net Assets
Latest net assets as of September 2025: NT$5.37 Billion TWD
Based on the latest financial reports, SCI Pharmtech Inc (4119) has net assets worth NT$5.37 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$6.85 Billion) and total liabilities (NT$1.48 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$5.37 Billion |
| % of Total Assets | 78.38% |
| Annual Growth Rate | 11.05% |
| 5-Year Change | 64.86% |
| 10-Year Change | 98.29% |
| Growth Volatility | 16.11 |
SCI Pharmtech Inc - Net Assets Trend (2002–2024)
This chart illustrates how SCI Pharmtech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SCI Pharmtech Inc (2002–2024)
The table below shows the annual net assets of SCI Pharmtech Inc from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$5.48 Billion | +7.39% |
| 2023-12-31 | NT$5.10 Billion | +40.52% |
| 2022-12-31 | NT$3.63 Billion | +9.29% |
| 2021-12-31 | NT$3.32 Billion | -0.05% |
| 2020-12-31 | NT$3.32 Billion | -4.39% |
| 2019-12-31 | NT$3.47 Billion | +8.24% |
| 2018-12-31 | NT$3.21 Billion | +9.57% |
| 2017-12-31 | NT$2.93 Billion | -4.60% |
| 2016-12-31 | NT$3.07 Billion | +11.18% |
| 2015-12-31 | NT$2.76 Billion | +24.07% |
| 2014-12-31 | NT$2.23 Billion | +7.65% |
| 2013-12-31 | NT$2.07 Billion | +63.88% |
| 2012-12-31 | NT$1.26 Billion | +11.55% |
| 2011-12-31 | NT$1.13 Billion | 0.00% |
| 2010-12-31 | NT$1.13 Billion | +9.00% |
| 2009-12-31 | NT$1.04 Billion | +10.11% |
| 2008-12-31 | NT$942.51 Million | +6.36% |
| 2007-12-31 | NT$886.14 Million | +14.05% |
| 2006-12-31 | NT$777.01 Million | +1.29% |
| 2004-12-31 | NT$767.10 Million | +2.19% |
| 2003-12-31 | NT$750.63 Million | +37.46% |
| 2002-12-31 | NT$546.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SCI Pharmtech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 437.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.53 Billion | 27.99% |
| Common Stock | NT$1.20 Billion | 21.82% |
| Other Comprehensive Income | NT$610.91 Million | 11.15% |
| Other Components | NT$2.14 Billion | 39.04% |
| Total Equity | NT$5.48 Billion | 100.00% |
SCI Pharmtech Inc Competitors by Market Cap
The table below lists competitors of SCI Pharmtech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
G8 Education Ltd
AU:GEM
|
$113.56 Million |
|
JADESTONE ENERGY LS -001
F:8KW
|
$113.61 Million |
|
451760
KQ:451760
|
$113.62 Million |
|
Remedy Entertainment Oyj
PINK:RMDEF
|
$113.64 Million |
|
Bitcoin Group SE
XETRA:ADE
|
$113.55 Million |
|
US Masters Residential Property Fund
PINK:UMRRF
|
$113.54 Million |
|
SNP Schneider-Neureither & Partner SE
XETRA:SHF
|
$113.53 Million |
|
AIC Mines Limited
PINK:IAUFF
|
$113.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCI Pharmtech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,099,953,000 to 5,476,932,000, a change of 376,979,000 (7.4%).
- Net income of 534,678,000 contributed positively to equity growth.
- Dividend payments of 149,387,000 reduced retained earnings.
- Other comprehensive income decreased equity by 28,525,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$534.68 Million | +9.76% |
| Dividends Paid | NT$149.39 Million | -2.73% |
| Other Comprehensive Income | NT$-28.52 Million | -0.52% |
| Other Changes | NT$20.21 Million | +0.37% |
| Total Change | NT$- | 7.39% |
Book Value vs Market Value Analysis
This analysis compares SCI Pharmtech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.03x to 1.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$13.44 | NT$54.20 | x |
| 2010-12-31 | NT$14.47 | NT$54.20 | x |
| 2011-12-31 | NT$14.47 | NT$54.20 | x |
| 2012-12-31 | NT$16.51 | NT$54.20 | x |
| 2013-12-31 | NT$19.51 | NT$54.20 | x |
| 2014-12-31 | NT$20.75 | NT$54.20 | x |
| 2015-12-31 | NT$25.58 | NT$54.20 | x |
| 2016-12-31 | NT$28.42 | NT$54.20 | x |
| 2017-12-31 | NT$27.11 | NT$54.20 | x |
| 2018-12-31 | NT$29.92 | NT$54.20 | x |
| 2019-12-31 | NT$31.58 | NT$54.20 | x |
| 2020-12-31 | NT$30.23 | NT$54.20 | x |
| 2021-12-31 | NT$30.41 | NT$54.20 | x |
| 2022-12-31 | NT$33.20 | NT$54.20 | x |
| 2023-12-31 | NT$46.53 | NT$54.20 | x |
| 2024-12-31 | NT$45.66 | NT$54.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SCI Pharmtech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.76%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 35.09%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.31x
- Recent ROE (9.76%) is below the historical average (11.21%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 15.28% | 16.37% | 0.63x | 1.47x | NT$28.83 Million |
| 2003 | 11.62% | 16.95% | 0.60x | 1.14x | NT$12.13 Million |
| 2004 | 5.45% | 9.12% | 0.51x | 1.17x | NT$-34.93 Million |
| 2006 | 5.92% | 8.93% | 0.59x | 1.12x | NT$-31.72 Million |
| 2007 | 16.99% | 18.75% | 0.76x | 1.20x | NT$61.90 Million |
| 2008 | 16.62% | 16.56% | 0.83x | 1.20x | NT$62.35 Million |
| 2009 | 16.02% | 18.36% | 0.72x | 1.21x | NT$62.53 Million |
| 2010 | 15.14% | 17.22% | 0.66x | 1.33x | NT$58.12 Million |
| 2011 | 7.96% | 8.67% | 0.68x | 1.34x | NT$-23.10 Million |
| 2012 | 15.41% | 15.40% | 0.80x | 1.25x | NT$68.26 Million |
| 2013 | 7.73% | 12.37% | 0.42x | 1.48x | NT$-46.86 Million |
| 2014 | 11.90% | 17.75% | 0.46x | 1.45x | NT$42.22 Million |
| 2015 | 13.54% | 20.65% | 0.52x | 1.25x | NT$97.70 Million |
| 2016 | 13.58% | 21.91% | 0.54x | 1.16x | NT$109.86 Million |
| 2017 | 6.52% | 14.68% | 0.39x | 1.12x | NT$-102.00 Million |
| 2018 | 13.93% | 23.05% | 0.51x | 1.18x | NT$126.21 Million |
| 2019 | 16.44% | 24.24% | 0.58x | 1.17x | NT$223.64 Million |
| 2020 | 10.84% | 13.39% | 0.59x | 1.38x | NT$27.90 Million |
| 2021 | 1.68% | 6.44% | 0.21x | 1.26x | NT$-276.37 Million |
| 2022 | 8.51% | 34.32% | 0.18x | 1.37x | NT$-54.14 Million |
| 2023 | 5.78% | 24.48% | 0.18x | 1.31x | NT$-215.27 Million |
| 2024 | 9.76% | 35.09% | 0.21x | 1.31x | NT$-13.02 Million |
Industry Comparison
This section compares SCI Pharmtech Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,317,013,700
- Average return on equity (ROE) among peers: 4.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCI Pharmtech Inc (4119) | NT$5.37 Billion | 15.28% | 0.28x | $113.56 Million |
| Grape King Bio Ltd (1707) | $2.08 Billion | 18.27% | 0.54x | $415.70 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $4.20 Billion | 8.11% | 0.48x | $159.99 Million |
| Maywufa Co Ltd (1731) | $1.41 Billion | 2.15% | 1.10x | $41.61 Million |
| Allied Biotech Corporation (1780) | $1.08 Billion | 1.21% | 1.26x | $48.27 Million |
| ScinoPharm Taiwan Ltd (1789) | $10.36 Billion | 2.77% | 0.13x | $179.96 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $23.77 Million |
| Easywell Biomedicals Inc. (1799) | $623.80 Million | -23.22% | 0.95x | $82.61 Million |
| LIWANLI Innovation Co Ltd (3054) | $897.52 Million | 5.08% | 0.06x | $51.25 Million |
| YungShin Global Holding Corp (3705) | $5.90 Billion | 12.21% | 0.47x | $295.98 Million |
| TTY Biopharm Co Ltd (4105) | $6.23 Billion | 17.56% | 0.54x | $484.94 Million |